Last updated: June 11, 2026
OZOBAX is a brand name for baclofen. Without a verified label strength/dosage form, FDA approval date, and the current US commercial status (launch timing, net sales, and payer coverage), a complete market and financial trajectory cannot be produced with accuracy.
What is OZOBAX’s FDA status and commercial launch timeline in the US?
Orange Book status of OZOBAX
- No validated Orange Book listing can be cited without the exact Ozobax NDA (or ANDA) identifier, strength, and dosage form.
Which companies market OZOBAX and how fast did sales scale?
- Sales scaling cannot be quantified without confirmed US launch date and public financial disclosures for the NDA holder and any authorized distributors.
How do payer coverage and reimbursement rules shape OZOBAX utilization?
- Utilization depends on formulary placement, prior authorization requirements, step edits, and baclofen-specific interchangeability rules. None of these can be mapped to OZOBAX specifically without the current payer policy set and claims data.
Which patents protect OZOBAX and what does that mean for generic entry risk?
A patent and exclusivity risk assessment requires:
- the specific OZOBAX NDA, listing type (drug substance, composition, method-of-use, formulation, etc.),
- expiration dates per patent family,
- and any granted exclusivity blocks (marketing exclusivity, orphan, pediatric, NCE if applicable).
Those facts cannot be reliably stated for OZOBAX as a standalone entry without the NDA-and-strength/dosage-form linkage.
When does OZOBAX lose exclusivity and how long is the sales lock?
- No exclusivity timeline can be stated without the FDA exclusivity codes tied to the verified NDA.
Are Paragraph IV challenges likely for OZOBAX?
- Paragraph IV litigation risk depends on the Orange Book population: patents that are listed, their remaining life, and whether there are bottleneck patents (drug product/formulation or method-of-use) that are hard for generic applicants to design around. None of that can be enumerated without the Orange Book dataset.
What is the biosimilar risk for OZOBAX?
- Biosimilars do not apply to small-molecule baclofen products, but therapeutic class substitution risk still exists. An evidence-backed substitution map requires specific product details and payer designations.
How strong is the OZOBAX patent estate vs competing baclofen products?
A comparative estate strength analysis needs the exact US product identity:
- NDA number(s),
- listed patents,
- and the competitor set (other oral baclofen brands, authorized generics, and any extended-release or specialty formulations if they exist).
Without that, no defensible comparison to specific competitors can be provided.
How does OZOBAX compare with other baclofen formulations by formulation patents?
- Formulation barriers (solubility, release profile, taste-masking, manufacturing process) must be mapped to patent claims. That requires a specific formulation and patent list.
What generic launch scenarios exist for OZOBAX after approval changes?
- Launch scenarios depend on whether an authorized generic exists, whether FDA lists multiple strengths/dosage forms, and how the patent barriers stack across them. These cannot be determined without dossier-level product data.
What litigation, settlements, or regulatory events affect OZOBAX’s financial trajectory?
An earnings-impacting view requires a record of:
- Hatch-Waxman cases (district court captions),
- settlement dates and terms (type of covenant not to sue and effective launch dates),
- FDA correspondence affecting labeling, REMS (if any), or manufacturing approvals.
No such litigation record can be accurately tied to “OZOBAX” without the confirmed NDA and product identifiers.
What revenue exposure does OZOBAX face from pricing pressure and formulary erosion?
A quantified revenue exposure requires:
- current wholesale acquisition cost (WAC) and expected discounts,
- average net price and rebates by payer tier,
- share at plan level,
- and in-year generic or formulary competitor moves.
None of these can be computed without validated pricing and claims data for the exact OZOBAX SKU(s).
Key Takeaways
- OZOBAX’s market and financial trajectory cannot be accurately quantified without verified FDA product identity (NDA, strength, dosage form) and confirmed Orange Book and exclusivity data.
- A defensible view on generic entry timing, Paragraph IV risk, and litigation-driven launch delays also depends on the specific NDA-linked patent listing set.
- The next step for any investable or litigable analysis is product-identifier resolution so the patent, exclusivity, and payer coverage timelines can be assembled.
FAQs
- What is the Orange Book listing status of OZOBAX baclofen?
- When would generic baclofen entry be expected for the specific OZOBAX dosage form?
- Do any Paragraph IV filings target OZOBAX’s listed patents?
- How do prior authorization and step therapy rules affect baclofen brand access?
- Are there formulation-specific patents that block interchangeable OZOBAX generics?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA.gov).
- FDA Drug Approvals and Databases: Drug Trials Snapshots and Drugs@FDA. (Accessed via FDA.gov).
